SCHEMBL1816665

SCHEMBL1816665

N#Cc1ncc(-c2ccn[nH]2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.53
POLB P06746 2/20 0.45
PTPN11 Q06124 1/20 0.45
HPGDS O60760 3/20 0.44
LTA4H P09960 2/20 0.40
SCN4A P35499 1/20 0.40
PDPK1 O15530 1/20 0.40
CYP2E1 P05181 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2B6 P20813 1/20 0.39
MET P08581 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
FTO Q9C0B1 1/20 0.37
PIM1 P11309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1820599 0.78 NOTUM (0.59) NOTUMPOLBPTPN11HPGDSSCN4A
Hydrochloric Acid SCHEMBL1817306 0.76 NOTUM (0.57) NOTUMPOLBPTPN11HPGDSSCN4A
SCHEMBL1813851 0.76 MAPT (0.45) NOTUMPOLBHPGDSLTA4HSCN4A
SCHEMBL1816188 0.75 NOTUM (0.65) NOTUMPOLBPTPN11SCN4APDPK1
Hydrochloric Acid SCHEMBL1814579 0.74 NOTUM (0.63) NOTUMPOLBPTPN11SCN4APDPK1
SCHEMBL1009701 0.72 ALDH1A1 (0.60) POLBKDM4EALDH1A1
SCHEMBL1810095 0.72 NOTUM (0.51) NOTUMPOLBPTPN11HPGDSLTA4H
Hydrochloric Acid SCHEMBL13733073 0.71 NOTUM (0.50) NOTUMPOLBPTPN11HPGDSLTA4H
SCHEMBL25296164 0.70 ALDH1A1 (0.50) POLBKDM4EALDH1A1
SCHEMBL30510157 0.70 ALDH1A1 (0.50) POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 EP disclosed
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2017-09-14 US disclosed
US-9657003-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2017-05-23 US disclosed
EP-3056485-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2016-08-17 EP disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 EP disclosed
CN-102596910-A Androgen receptor modulating compounds ORION CORP 2012-07-18 CN disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260206-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NOTUM 2394/4885POLB 4437/4885PTPN11 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.